Desktop Genetics develops technologies at the intersection of biotechnology, information management and laboratory automation. We make genetic engineering as easy, cost-efficient and rapid as it ought to be.
With more people, companies and industries getting involved in the synthetic biology revolution, the ability to build superior quality DNA in record time is central to unlocking the potential of applied biology.
That's why we're developing AutoClone
, a software tool that pools and intelligently shares your DNA sequence inventory with your colleagues. Using our patent-pending technology, AutoClone automatically works out the best way to recycle existing genes and plasmids into new ones. The resulting instructions can then be executed by hand or passed to a lab robot.
We emphasize the right tool for the right job - and so we're building the very tools that we always wanted in our own labs to save us time, money and a whole lot of stress.
The Desktop Genetics team came together to make genetic engineering more accessible and efficient than it ever has been before. A dynamic and young trio that met at the University of Cambridge MPhil Bioscience Enterprise programme, you'll find us out and about during the day talking with our customers about what they need, while our nights are spent staying up late to hammer out new software products for the synthetic biology revolution. We're expanding the team and welcome prospective CVs.
Motivated to realise the business impacts of combining synthetic biology, biotech information and automation, Riley has long dreamt of designing the "killer app" for the biotech industry. After spending several years working for Genentech as a bioprocess engineer, Riley brought together the DeskGen team to do just that, where he leads the technical development.
A chemical engineer by training, Victor has long been inspired by the potential of synthetic biology to revolutionise manufacturing strategies and suply chains in chemical, pharmaceutical and consumer goods industries. Victor leads on finance and operations where his experience at Proctor & Gamble, GSK and Flagship Ventures are invaluable.
A biologist with a bioveterinary background, Edward combines business experience with molecular biology, having worked with Kymab to identify strategies for commercialising antibody technologies, as well as the EU Research and Innovation division. Edward has strong interest in public engagement with synthetic biology and leads on business development and regulatory strategy.